Abstract:Background: Gap junctions, which serve as intercellular channels that allow the passage of ions and other small molecules between neighboring cells, play an important role in vital functions, including the regulation of cell growth, differentiation, and development. Statins, the 3-hydroxy-3-methylglutaryl-coenzymeA (HMG-CoA) reductase inhibitors, have been shown to inhibit the migration and proliferation of smooth muscle cells (SMCs) leading to an antiproliferative effect. Recent studies have shown that statins can reduce gap junction protein connexin43 (Cx43) expression both in vivo and in vitro. However, little work has been done on the effects of statins on gap junctional intercellular communication (GJIC). We hypothesized in this study that lovastatin inhibits vascular smooth muscle cells (VSMCs) migration through the inhibition of the GJIC. Methods: Rat aortic SMCs (RASMCs) were exposed to lovastatin. Vascular smooth muscle cells migration was then assessed with a Transwell migration assay. Gap junctional intercellular communication was determined by using fluorescence recovery after photobleaching (FRAP) analysis, which was performed with a laser-scanning confocal microscope. Results: The migration of the cultured RASMCs were detected by Trans. well system. Cell migration was dose-dependently inhibited with lovastatin. Compared with that in the control (110 +/- 26), the number of migrated SMCs was significantly reduced to 72 +/- 24 (P < .05), 62 +/- 18 (P < .01), and 58 +/- 19 (P < .01) at the concentration of 0.4, 2, and 10 umol/L, per field. The rate of fluorescence recovery (R) at 5 minutes after photobleaching was adopted as the functional index of GJIC. The R- value of cells exposed to lovastatin 10 umol/L for 48 hours was 24.38% +/- 4.84%, whereas the cells in the control group had an R- value of 36.11% +/- 10.53%, demonstrating that the GJIC of RASMCs was significantly inhibited by lovastatin (P < .01). Smaller concentrations of lovastatin 0.08 umol/L did not change gap junction coupling (P > .05). Conclusions: These results suggest that lovastatin inhibits migration in a dose-dependent manner by attenuating JIC. Suppression of gap junction function could add another explanation of statin-induced antiproliferative effect.

Lovastatin Blocks Kv1.3 Channel in Human T Cells: a New Mechanism to Explain Its Immunomodulatory Properties

Lovastatin inhibits gap junctional communication in cultured aortic smooth muscle cells.

Effects of lovastatin on expression of hypoxia inducible factor 1 alpha on U937 cell induced by oxidized low density lipoprotein

Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells.

T Cell Subset and Stimulation Strength-Dependent Modulation of T Cell Activation by Kv1.3 Blockers

Lovastatin Reduces Nuclear Factor Kappa B Activation Induced by C-Reactive Protein in Human Vascular Endothelial Cells

Regulation of Lovastatin on a Key Inflammation-Related Microrna in Myocardial Cells.

The regulation of lovastatin on transforming growth factorβ1 and interleukin-6 in cardiac myocytes

Quantitative Proteomic Analysis Revealed Lovastatin-Induced Perturbation of Cellular Pathways in Hl-60 Cells

Lovastatin Increases Nitric Oxide Synthesis in IL-1 Beta-Stimulated Smooth Muscle Cells.

Simvastatin Suppresses the Proangiogenic Microenvironment of Human Hepatic Stellate Cells Via the Kruppel-like Factor 2 Pathway.

Lovastatin-mediated Pharmacological Inhibition of Formin Protein DIAPH1 Suppresses Tumor Immune Escape and Boosts Immunotherapy Response

Specific Kv1.3 blockade modulates key cholesterol-metabolism-associated molecules in human macrophages exposed to ox-LDL

Integrin β3 and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic cholangiocarcinoma.

Hexokinase 2 is a Pivot for Lovastatin-induced Glycolysis-to-Autophagy Reprogramming in Triple-Negative Breast Cancer Cells

Simvastatin Inhibits IL-17 Secretion by Targeting Multiple IL-17-Regulatory Cytokines and by Inhibiting the Expression of IL-17 Transcription Factor RORC in CD4+ Lymphocytes

Lovastatin Inhibits Toll-like Receptor 4 Signaling in Microglia by Targeting Its Co-Receptor Myeloid Differentiation Protein 2 and Attenuates Neuropathic Pain.

Off-Target Effect of Lovastatin Disrupts Dietary Lipid Uptake and Dissemination through Pro-Drug Inhibition of the Mesenteric Lymphatic Smooth Muscle Cell Contractile Apparatus

Statins attenuate high mobility group box-1 protein induced vascular endothelial activation : a key role for TLR4/NF-κB signaling pathway

Lovastatin Changes Activities of Lactate Dehydrogenase A and B Genes in Rat Myocardial Cells.

Acacetin Blocks Kv1.3 Channels and Inhibits Human T Cell Activation